{"id":39124,"date":"2026-05-20T11:43:26","date_gmt":"2026-05-20T15:43:26","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39124"},"modified":"2026-05-20T11:42:20","modified_gmt":"2026-05-20T15:42:20","slug":"the-hidden-ip-trap-in-clinical-research-how-unvetted-software-and-ai-imperil-sponsor-patents","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-hidden-ip-trap-in-clinical-research-how-unvetted-software-and-ai-imperil-sponsor-patents\/","title":{"rendered":"The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Imperil Sponsor Patents"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Darshan Kulkarni PharmD, MS, Esq.<\/p>\n\n\n\n

Introduction<\/h1>\n\n\n\n

The intersection of intellectual property (IP) and artificial intelligence (AI) has triggered a tidal wave of regulatory and legal uncertainty. Neither governing bodies nor private enterprises have fully grasped how to regulate IP in an era where AI models are routinely trained on proprietary data. Rather than proactively resolving these boundaries, many tech companies operate under a “move fast and break things” ethos. This means that they are open to violating IP rights first and opting to settle litigation after the fact.<\/p>\n\n\n\n

While this dynamic has proven exceptionally painful for authors and copyright holders, a quieter but equally devastating crisis is brewing in the realm of patents and trade secrets. This risk is heavily underscored by the tension between recent, conflicting judicial opinions regarding AI disclosures, privacy, data sharing, and confidentiality.<\/p>\n\n\n\n

The Confidentiality Catch-22: Conflicting Judicial Perspectives<\/h1>\n\n\n\n

To understand the risk AI poses to proprietary data, one must look at how courts currently view AI interactions through the lens of privilege and confidentiality. Recent jurisprudence highlights a stark judicial divide.<\/p>\n\n\n\n

For instance, in the Warner v. Gilbarco, Inc . et al<\/a> decision, the court took a permissive approach to technology. The judge ruled that an attorney\u2019s review of information via a public-facing AI tool was no different from utilizing any other standard legal research software. Consequently, the interaction was protected under the attorney work-product doctrine.<\/p>\n\n\n\n

Conversely, a recent decision by Judge Rakoff in United States v. Heppner<\/em><\/a> established a much stricter boundary. In that case, the court held that if an individual (i.e., a non-attorney) utilizes a public-facing Large Language Model (LLM) to organize their thoughts, that interaction constitutes a non-confidential disclosure. As a result, attorney-client privilege is waived.<\/p>\n\n\n\n

For litigants and corporate counsel, the implications are dramatic: feeding proprietary logic or data into an unvetted AI tool can legally extinguish its confidential status.<\/p>\n\n\n\n

Clinical Research Sites: Prioritizing Feasibility Over IP Compliance<\/h1>\n\n\n\n

This confidentiality crisis is manifesting rapidly within clinical research. Research sites are increasingly adopting third-party software vendors to streamline operations. These tech platforms directly connect patient and trial databases to automate crucial tasks: checking inclusion\/exclusion criteria, identifying potential subjects, and scheduling screening visits.<\/p>\n\n\n\n

While these software vendors often tout “HIPAA-compliant” precautions, they frequently operate without the explicit consent of the clinical trial sponsor or the subjects themselves. In practice, research sites and software vendors are prioritizing compliance with FDA subject-suitability requirements at the expense of the site’s clinical trial agreement (CTA) with the sponsor. By doing so, they routinely violate contractual provisions governing intellectual property, publication restrictions, and data privacy.<\/p>\n\n\n\n

The Triple Threat to Sponsor Intellectual Property<\/h1>\n\n\n\n

When a research site exposes a sponsor’s clinical data to an unvetted software or AI vendor, it triggers a domino effect of catastrophic IP consequences.<\/p>\n\n\n\n

1. The Destruction of Trade Secrets<\/h2>\n\n\n\n

Trade secrets remain protectable only as long as they are kept secret. While the law offers narrow safe harbors for inadvertent disclosures caused by third-party malfeasance, these protections evaporate if the disclosure is deemed intentional.<\/p>\n\n\n\n

As recent jurisprudence suggests, courts increasingly view the affirmative uploading of data into an AI tool or third-party platform as an intentional act. When a site exposes a sponsor\u2019s protocol, data, or operational metrics to a vendor, those trade secrets may be legally compromised at the exact moment of creation.<\/p>\n\n\n\n

2. Triggering the Publication Bar<\/h2>\n\n\n\n

When proprietary clinical data is leaked to a software vendor, the financial and legal fallout can be immediate. Courts have consistently held that even minimal disclosures<\/a> of data to unauthorized third parties can be legally construed as a “public disclosure.”<\/p>\n\n\n\n

Under patent law, such an event would constitute a publication. A public disclosure by a research site, to a software vendor, may constitute a publication and trigger the one-year clock to file a patent application. However, if a sponsor doesn\u2019t even know such a trigger has occurred, it is unlikely an application will be filed within the one year grace period. Failure to file a timely patent application can result in an irrevocable loss of patent rights.  What is worse, since most foreign countries do not offer a one-year grace period, a public disclosure will most likely prevent the sponsor from applying for and\/or receiving foreign patents. <\/p>\n\n\n\n

3. Triggering the On-Sale Bar<\/h2>\n\n\n\n

Courts have historically maintained an expansive definition of what constitutes a “sale” under the \u201con-sale\u201d bar. If a clinical site is provided free or discounted software by a vendor in exchange for access to trial data (which belongs to the sponsor), a court may well view this quid pro quo<\/em> as a commercial sale of the technology.<\/p>\n\n\n\n

This triggers a strict one-year clock to file a timely patent application. Because sponsors are completely unaware the site made this data-for-software exchange, the one-year window frequently expires without a patent application being filed, permanently dedicating the invention to the public domain.<\/p>\n\n\n\n

The Long-Term Fallout: The Hatch-Waxman Vulnerability<\/h1>\n\n\n\n

The true crisis of these unauthorized software integrations won’t be felt today or tomorrow. It will hit five to ten years down the road.<\/p>\n\n\n\n

Imagine a scenario where a sponsor successfully brings a multi-billion-dollar drug to market. A generic manufacturer launched a Hatch-Waxman patent challenge. During discovery, the generic challenger uncovers that years prior, an unauthorized software vendor at a clinical site scraped the trial data, triggering an un-remedied publication or on-sale bar.<\/p>\n\n\n\n

With a single evidentiary finding, a sponsor’s foundational patents could be held invalid, wiping out billions in market share.<\/p>\n\n\n\n

Strategic Takeaways for Sponsors<\/h1>\n\n\n\n

To safeguard their IP portfolios, clinical trial sponsors must take immediate, proactive steps:<\/p>\n\n\n\n

    \n
  • Mandate Site Education & Audits:<\/strong> Sponsors must aggressively educate clinical research sites on the dangers of utilizing unauthorized, non-sponsor-approved software. This applies not just to known platforms, but to any unvetted data-aggregator or AI tool.<\/li>\n\n\n\n
  • Strengthen CTA Enforcement:<\/strong> Clinical Trial Agreements must include explicit, heavy penalties for the unauthorized use of third-party software that touches trial data.<\/li>\n\n\n\n
  • Build Walled Gardens:<\/strong> Sponsors should establish preferred partnerships with vetted software vendors. They must ensure all technological tools utilized by sites operate strictly within a secure, contractually protected “walled garden” that completely prevents data leakage outside the sponsor\u2019s ecosystem.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    Darshan Kulkarni PharmD, MS, Esq. Introduction The intersection of intellectual property (IP) and artificial intelligence (AI) has triggered a tidal […]<\/p>\n","protected":false},"author":1,"featured_media":39125,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39124"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39124\/revisions"}],"predecessor-version":[{"id":39127,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39124\/revisions\/39127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39125"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}